Immunome (NASDAQ:IMNM) Insider Robert Lechleider Sells 55,000 Shares

Immunome, Inc. (NASDAQ:IMNM) insider Robert Lechleider sold 55,000 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $19.85, for a total value of $1,091,750.00. Following the completion of the sale, the insider owned 15,805 shares of the company’s stock, valued at approximately $313,729.25. The trade was a 77.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Immunome Stock Up 5.4%

Shares of IMNM opened at $21.04 on Tuesday. Immunome, Inc. has a 52-week low of $7.96 and a 52-week high of $27.65. The stock has a fifty day simple moving average of $21.09 and a two-hundred day simple moving average of $21.74. The company has a market capitalization of $2.38 billion, a PE ratio of -8.84 and a beta of 2.04.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.12. As a group, equities analysts anticipate that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of IMNM. T. Rowe Price Investment Management Inc. raised its stake in shares of Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after acquiring an additional 5,003,824 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Immunome by 23.4% in the 4th quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after acquiring an additional 1,144,788 shares during the last quarter. Primecap Management Co. CA boosted its position in shares of Immunome by 55.2% during the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after purchasing an additional 1,667,432 shares during the period. State Street Corp boosted its position in shares of Immunome by 37.9% during the 4th quarter. State Street Corp now owns 3,868,000 shares of the company’s stock worth $83,085,000 after purchasing an additional 1,064,027 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in Immunome by 8,659.2% in the 4th quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock valued at $61,341,000 after purchasing an additional 2,823,144 shares during the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Craig Hallum increased their price target on shares of Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Immunome in a research report on Wednesday, May 13th. Truist Financial upped their price objective on Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, May 28th. Stephens lowered their price objective on Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a research report on Wednesday, March 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research note on Tuesday, April 21st. Twelve investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $33.17.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.